Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review.

Autor:	Di Vincenzo M; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Martiadis V; Department of Mental Health, Community Mental Health Center DS 25, Azienda Sanitaria Locale Napoli 1 Centro, Naples, Italy., Della Rocca B; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Arsenio E; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., D'Arpa A; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Volpicelli A; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Luciano M; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Sampogna G; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy., Fiorillo A; Department of Psychiatry, University of Campania 'L. Vanvitelli', Naples, Italy.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2024 May 15; Vol. 15, pp. 1394787. Date of Electronic Publication: 2024 May 15 (Print Publication: 2024).
DOI:	10.3389/fpsyt.2024.1394787
Abstrakt:	Introduction and Aims: Treatment-resistant depression (TRD) occurs when at least two different antidepressants, taken at the right dosage, for adequate period of time and with continuity, fail to give positive clinical effects. Esketamine, the S-enantiomer of ketamine, was recently approved for TRD treatment from U.S. Food and Drug Administration and European Medicine Agency. Despite proved clinical efficacy, many misconceptions by clinicians and patients accompany this medication. We aimed to review the most common "false myths" regarding TRD and esketemine, counterarguing with evidence-based facts. Methods: The keywords "esketamine", "treatment resistance depression", "depression", "myth", "mythology", "pharmacological treatment", and "misunderstanding" were entered in the main databases and combined through Boolean operators. Results: Misconceptions regarding the TRD prevalence, clinical features and predictors have been found. With respect of esketamine, criteria to start treatment, dissociative symptoms, potential addiction and aspects of administration and monitoring, were found to be affected by false beliefs by clinicians and patients. Discussion and Conclusion: TRD represents a challenging condition, requiring precise diagnosis in order to achieve patient's full recovery. Esketamine has been proved as an effective medication to treat TRD, although it requires precautions. Evidence can inform clinical practice, in order to offer this innovative treatment to all patients with TRD. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Di Vincenzo, Martiadis, Della Rocca, Arsenio, D’Arpa, Volpicelli, Luciano, Sampogna and Fiorillo.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu